AtriCure, Inc. is a medical device company specializing in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. Its cardiac ablation and LAA management products are used by physicians during open-heart and minimally invasive surgical procedures, including concomitant surgeries for conditions like valve repair or coronary artery bypass, as well as standalone hybrid approaches. The company’s pain management solutions utilize cryoICE technology to freeze nerves during cardiac, thoracic, or amputation surgeries to provide temporary relief of post-operative pain. AtriCure sells its products to medical centers through a direct sales force in the United States, Germany, France, the United Kingdom, the Benelux region, Australia, and Canada, and through distributors in other international markets. Its primary customers are cardiothoracic surgeons, electrophysiologists, and thoracic surgeons. The company’s portfolio includes the Isolator Synergy Ablation System, the AtriClip Left Atrial Appendage Exclusion System, the EPi-Sense ablation system, and cryoICE cryoSPHERE and cryoXT probes.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage atricure.com
Sector Healthcare IR page atricure.com
Tags
atrial fibrillation, surgical ablation, left atrial appendage management, cryo nerve block, pain management, cardiac surgery, hybrid therapy, medical devices, Isolator Synergy Ablation System, AtriClip Left Atrial Appendage Exclusion System, EPi-Sense ablation system, cryoICE cryoSPHERE, cryoXT probe, cryoICE cryoSPHERE+, cryoSPHERE MAX, EnCompass clamp, Hybrid AF Therapy
Press page —

Metrics

Valuation  
Market cap $ 2.977B
Market cap (USD) $ 2.977B
P/E 200.05
PEG —
P/BV 5.58
P/S 5.05
P/OCF 43.44
P/FCF 56.24
Dividend yield —
Turnover / mcap —
Returns  
ROE -2.4%
ROI -2.1%
ROIC -1.3%
Profit margin -2.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 11.4%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 30
Quality score -5.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004
Revenue 534.528M 465.307M 399.245M 330.379M 274.329M 206.531M 230.807M 201.63M 174.716M 155.109M 129.755M 107.454M 81.889M 70.247M 64.402M 59.006M 54.534M 55.257M 48.309M 38.243M 30.957M 19.157M
Net profit -11.448M -44.698M -30.438M -46.466M 50.199M -48.155M -35.194M -21.137M -26.892M -33.338M -27.212M -16.211M -11.462M -7.534M -5.456M -3.792M -16.495M -10.167M -11.253M -13.717M -12.683M -9.452M
Free cash flow 48.284M 745K -7.514M -39.022M -23.533M -25.128M -27.993M -10.382M -15.328M -22.811M -21.287M -30.807M -8.086M -4.921M -3.509M -1.847M -940.511K -7.458M -11.16M -14.146M -9.568M -5.313M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004
Share price 39.56 30.56 35.69 44.38 69.53 55.67 32.51 30.6 18.24 19.57 22.44 19.96 18.68 6.91 12.14 10.2 5.43 2.28 11 6 11.16 —
Price performance 12m 0.29 -0.14 -0.2 -0.36 0.25 0.71 0.06 0.68 -0.07 -0.13 0.12 0.07 1.7 -0.43 0.19 0.88 1.38 -0.79 0.83 -0.46 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 21.1M 23.1M 25.2M 28M 23.1M 33M 42.7M 52.5M 60.3M 66.7M
↳ YoY growth +8.7% +9.4% +9.1% +11.3% -17.5% +42.7% +29.3% +23.0% +14.9% +10.5%
↳ 5y CAGR +17.3% +18.3% +13.0% +9.8% +3.6% +9.4% +13.1% +15.8% +16.6% +23.6%
Borrowings, current (USD) 1.69M 561,000 4.43M — 6.67M — 5.47M 2.53M 2.81M —
Borrowings, non-current (USD) 23.9M 24.1M 35.6M 59.6M 53.4M 59.7M 56.8M 60.6M 61.9M 61.9M
Lease liabilities (USD) — — 12.2M 16.8M 13M 15.9M 14.4M 13.9M 14.7M 14.6M
Cash and deposits (USD) 24.2M 21.8M 32.2M 28.5M 41.9M 43.7M 58.1M 84.3M 123M 167M
Intangible assets (USD) 52.1M 50.8M 49.3M 130M 128M 43M 39.3M 64M 56.5M 48M
Right-of-use assets (USD) — — — 4.03M 1.91M 4.76M 3.79M 4.32M 5.73M 6.87M
Net debt (borrowings + leases - cash) (USD) 1.37M 2.85M 7.77M 47.9M 31.1M 32M 13.1M -7.28M -43.4M -91M
Cash flow detail
Operating cash flow (USD) -15.1M -8.94M -4.17M -15.8M -19.9M -13.8M -22.1M 4.48M 12.2M 57.3M
Purchases of property, plant and equipment (USD) -7.69M -6.38M -6.21M -12.2M -5.26M -9.75M -16.9M -12M -11.5M -9.05M
Purchases of intangible assets (USD) — — — — — 0.00 0.00 -30M -12M —
Change in receivables (cash effect) (USD) -1.98M -1.46M -2.84M -3.2M 5.09M -10.1M -8.99M -9.87M -8.3M -5.61M
Change in inventories (cash effect) (USD) -79,000 -4.48M -146,000 -5.15M -5.27M -4.27M -7.31M -21.8M -7.74M -2.26M
Change in payables (cash effect) (USD) -1.07M 1.29M -2.4M 2.79M -1.56M 4.71M 2.68M 6.18M -1.53M -960,000
Interest paid (cash effect) (USD) -1.51M -2M -3.87M -3.72M -4.37M -4.22M -4.27M -6.38M -5.95M -5.26M
Income taxes paid (cash effect) (USD) -30,000 -37,000 -65,000 -259,000 -217,000 -190,000 -192,000 -395,000 -619,000 -1.29M
Share-based compensation (USD) 11.7M 14.6M 16.5M 18M 22.6M 28.1M 28.8M 35.7M 40.4M 44.7M
Operating cash flow before change in receivables (USD) -13.1M -7.48M -1.33M -12.6M -25M -3.69M -13.2M 14.4M 20.5M 62.9M
Free cash flow (OCF - PPE - intangibles) (USD) -22.8M -15.3M -10.4M -28M -25.1M -23.5M -39M -37.5M -11.3M 48.3M
Income detail
Research and development expense (USD) 35.8M 34.1M 34.7M 41.2M 43.1M 48.5M 57.3M 73.9M 96.2M 99.2M
↳ 5y CAGR +24.8% +23.0% +20.9% +17.3% +10.8% +6.2% +10.9% +16.3% +18.5% +18.2%
Total comprehensive income (USD) -33.2M -26.4M -21.4M -35.2M -47.7M 48.9M -49.6M -27.3M -44.7M -9.85M
Comprehensive income to owners (USD) -33.2M -26.4M -21.4M -35.2M -47.7M 48.9M -49.6M -27.3M -44.7M -9.85M
Provision for credit losses (USD) — — — — 0.00 65,000 190,000 270,000 50,000 200,000
Credit cost ratio (credit losses / average receivables) (%) — — — — 0.0% 0.2% 0.5% 0.6% 0.1% 0.3%
Reported Mar 8, 2017 Feb 28, 2018 Apr 26, 2019 Feb 24, 2020 Feb 22, 2023 Feb 16, 2024 Feb 16, 2024 Feb 16, 2024 Feb 14, 2025 Feb 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Third Quarter 2026 worldwide revenue of $154.5 million, an increase of 15.0% year over year

•Profitability expansion in the Third Quarter 2026, with net income of $4.1 million and adjusted EBITDA of $26.8 million

MASON, Ohio, November 3, 2026 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2026 financial results.

“Our third quarter results demonstrate the strength of our broad portfolio and our team’s disciplined execution,” said Michael Carrel, President and Chief Executive Officer. “Adoption of our innovative technologies is driving strong growth and expanding profitability, while the rapid progress of our BoxX-NoAF clinical trial reinforces our confidence in the opportunities ahead.

•Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year

•Second Quarter 2026 profitability strengthened, with net income of $9.0 million and adjusted EBITDA of $27.3 million

•Second Quarter 2026 cash generation of $21.6 million

MASON, Ohio, July 23, 2026 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results.

“Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said Michael Carrel, President and Chief Executive Officer. “Our innovative technologies continue to prove their value, with strong growth in pain management bolstering our leading cardiac surgery portfolio. Meanwhile, we are rapidly advancing our BoxX-NoAF and LeAAPS clinical trials towards data readouts that we believe will inform and drive the next era of cardiac surgery patient care and growth for AtriCure.

July 21, 2026

What began as routine care for atrial fibrillation became an opportunity for a more lasting solution. After 14 years of living with Afib, Gloria Lawless arrived for a cardioversion treatment, but an additional scan revealed a rare tumor hidden in her heart. This discovery changed her treatment plan and gave doctors a unique chance to treat her irregular heart rhythm directly.

During open-heart surgery to remove the atrial myxoma, surgeons also performed a Cox-Maze procedure to treat Gloria’s Afib. This procedure blocked the abnormal electrical signals that cause Afib but kept her heart’s normal rhythm working. Because she was already having surgery, the team could fix both issues at once by removing the tumor and helping her chances for long-term rhythm control.

Gloria felt better from the Afib treatment almost right away. Within a day, she was walking the halls and breathing more easily than she had in months. Now she’s working toward skydiving for the first time as part of her 70th birthday celebration.

For people who have lived with Afib for years, Gloria’s story shows that surgical ablation to treat Afib can do more than fix a heartbeat. It can help people get back to living their lives.

Prompts

AtriCure, Inc. (ticker ATRC), listed in United States.

ETFs Holding AtriCure, Inc.

ETF Weight in ETF Shares Market value As of
SCDS 0.30% 503 $ 27.675K Nov 17, 2026
EHLS 0.30% 2,945 $ 162.888K Nov 17, 2026
FSEG 0.24% 496 $ 13.878K Jun 30, 2026
FESM 0.22% 461,390 $ 12.91M Jun 30, 2026
MMSC 0.18% 1,644 $ 90.93K Nov 16, 2026
MSSM 0.15% 21,802 $ 1.054M Aug 31, 2026
SYZ 0.14% 3,489 $ 97.622K Jun 30, 2026
PSC 0.08% 65,292 $ 1.827M Jun 30, 2026
RESM 0.06% 83 $ 2,322.34 Jun 30, 2026
DFAS 0.06% 342,769 $ 19.188M Nov 12, 2026
FEAC 0.04% 390 $ 10.912K Jun 30, 2026
DFSU 0.01% 4,896 $ 274.078K Nov 12, 2026
DFAC 0.01% 175,311 $ 9.814M Nov 12, 2026
DCOR 0.01% 52,297 $ 2.928M Nov 12, 2026
DFAU 0.01% 13,540 $ 757.969K Nov 12, 2026
DFUS 0.00% 14,970 $ 838.021K Nov 12, 2026
DXUV 0.00% 1,248 $ 69.863K Nov 12, 2026
EBI 0.00% 4 $ 193.40 Aug 31, 2026
AVUS 0.00% 288 $ 15.929K Nov 16, 2026
AVSU 0.00% 95 $ 5,254.45 Nov 16, 2026